Clinical trial
Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed…
NCT00028847 · Commissie Voor Klinisch Toegepast Onderzoek, Other · Unknown status
Key facts
| NCT number | NCT00028847 |
|---|---|
| Title | Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia |
| Official title | A Dose-ranging Phase I/II Study of STI571 in Combination With Cytarabin in Patients With First Chronic Phase Chronic Myeloid Leukemia |
| Lead sponsor | Commissie Voor Klinisch Toegepast Onderzoek, Other |
| Status | Unknown status |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | cytarabine, imatinib mesylate |
| Enrollment | 60 |
| Start date | Apr 1, 2001 |
| First posted | Jan 27, 2003 |
| Last update posted | Sep 17, 2013 |
| Countries | Belgium, Netherlands |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: